Generic Name and Formulations:
Desogestrel 0.15mg, ethinyl estradiol 30micrograms (21 tabs); inert (7 tabs).
Merck & Co., Inc.
1 tab daily for 28 days; repeat.
Pre-menarche: not applicable.
Thrombophlebitis or thromboembolic disorders. Cerebral vascular or coronary artery disease. Valvular heart disease with thrombogenic complications. Severe hypertension. Diabetes with vascular involvement. Headaches with focal neurologic symptoms. Major surgery with prolonged immobilization. Breast or other estrogen-dependent neoplasms. Undiagnosed abnormal genital bleeding. Cholestatic jaundice of pregnancy or jaundice with prior OC use. Hepatic disease or tumors. Smokers (≥15 cigarettes/day) over age 35. Pregnancy (Cat.X). Concomitant ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.
Increased risk of cardiovascular events esp. in cigarette smokers >35yrs of age. Discontinue if thrombotic event, unexplained visual changes, jaundice, migraine or other severe headaches occur, and at least 4 weeks before through 2 weeks after surgery associated with increased risk of thromboembolism. Gallbladder disease. Diabetes. Prediabetes. Uncontrolled dyslipidemias. Hypertriglyceridemia. Depression. Fluid rentention. Monitor blood pressure. Hepatic or renal impairment. Do regular complete physical exams. May need barrier contraception with Sunday starts or postpartum use (see full labeling). Nursing mothers: not recommended.
See Contraindications. ALT elevations with HCV regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir; discontinue Desogen prior to starting HCV regimen and restart 2wks after completion. May be antagonized by barbiturates, rifampin, phenylbutazone, phenytoin, carbamazepine, felbamate, oxcarbazepine, topiramate, griseofulvin, St. John's wort. May be potentiated by atorvastatin, ascorbic acid, acetaminophen, itraconazole, ketoconazole. May be affected by protease inhibitors. May potentiate cyclosporine, prednisolone, theophylline. May antagonize acetaminophen, temazepam, salicylic acid, morphine, clofibric acid. May affect laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins).
Progestin + estrogen.
Nausea, vomiting, breakthrough bleeding, amenorrhea, transient delay of ovulation after discontinuation, edema, chloasma, headache, weight changes, intolerance to contact lenses; serious thromboembolic events, liver disease, hypertension.
Join MIMS Learning now to manage all your CPD and notes in one place!
Already a MIMS Learning member?Sign In Now »
This red flags article explains signs and symptoms of potentially serious pathology in patients presenting...
This article by Dr Tillmann Jacobi covers the possible red flag symptoms to consider when a patient...
Dr Suneeta Kochhar provides an overview of red flag symptoms in patients presenting with headaches...
In this article, Dr David Brass and Dr Neil Rajan discuss the risk factors for BCC, making the diagnosis...
This article by Dr Rajiv Sankaranarayanan covers the diagnosis and management of cardiomyopathy. Key...
Dr Benjamin Simpson provides an in-depth overview of Parkinson’s disease, including information on risk...